Novo Nordisk A/S: Trading In Novo Nordisk Shares By Board Members, Executives And Associated Persons
Date
8/30/2024 4:46:00 AM
(MENAFN- GlobeNewsWire - Nasdaq) Bagsværd, Denmark, 30 August 2024 - This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| | Details of the person discharging managerial responsibilities/person closely associated |
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument,
type of instrument, | ADRs
| |
| | Identification code | NVO | |
| b) | Nature of the transaction | Purchase of ADRs | |
c)
| Price(s) and volume(s)
| | | | | |
| | Price(s) | Volume(s) | | |
| | DKK 904.41 | 12.742 ADRs | | |
| | DKK 904.35 | 4.047 ADRs | | |
| | | | | |
| d) | Aggregated information |
16.789 ADRs
DKK 15,183.93 | |
| e) | Date of the transaction | 2024-08-28 | |
| f) | Place of the transaction | New York Stock Exchange | |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube .
Contacts for further information
| Media: | |
Ambre James-Brown
+45 3079 9289
...
| Liz Skrbkova (US)
+1 609 917 0632
... |
| Investors: | |
Jacob Martin Wiborg Rode
+45 3075 5956
...
| David Heiberg Landsted
+45 3077 6915
...
|
Sina Meyer
+45 3079 6656
...
| Mark Joseph Root (US)
+1 848 213 3219
...
|
Ida Schaap Melvold
+45 3077 5649
... | Frederik Taylor Pitter
+45 3075 8259
... |
Company announcement No 67 / 2024
Attachment
MENAFN30082024004107003653ID1108618642
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.